Acute Lymphoblastic Leukemia (ALL): Overview

Acute lymphoblastic leukemia (ALL) is a fast-growing cancer of the lymphoid line of blood cells. It originates in the bone marrow, where immature lymphocytes (lymphoblasts) proliferate uncontrollably, crowding out normal hematopoiesis and spilling into peripheral blood and other organs.

Key Facts

  • Most common childhood cancer (peak 2-5 years), but also occurs in adults.
  • Subtypes: B-cell ALL (~85%), T-cell ALL (~15%).
  • Genetic alterations (e.g., ETV6-RUNX1, BCR-ABL1, KMT2A rearrangements) guide risk stratification and therapy.

Presentation

  • Fatigue, pallor (anemia)
  • Fever, infections (neutropenia)
  • Bruising, bleeding (thrombocytopenia)
  • Bone/joint pain, lymphadenopathy, hepatosplenomegaly

Treatment & Prognosis

Multi-agent chemotherapy (induction, consolidation, maintenance) ± targeted therapy (TKIs for Ph+ ALL) ± CNS prophylaxis ± hematopoietic stem cell transplant for high-risk/relapsed disease. Pediatric cure rates exceed 90%; adult outcomes are improving but remain lower.

Medical Billing - Related Articles